Melanoma: What do all the mutations mean?

Melanoma is one of the most highly mutated malignancies, largely as a function of its generation through ultraviolet light and other mutational processes. The wide array of mutations in both “driver” and “passenger” genes can present a confusing array of data for practitioners, particularly within the context of the recent revolutions in targeted and immune therapy. Although mutations in BRAF V600 clearly confer sensitivity to BRAF and mitogen‐activated protein kinase kinase (MEK) inhibitors, the clinical implications of most other mutations are less often discussed and understood. In this review, we provide an overview of the high‐frequency genomic alterations and their prognostic and therapeutic relevance in melanoma.

[1]  Yu-Ying He,et al.  Mechanisms and prevention of UV‐induced melanoma , 2018, Photodermatology, photoimmunology & photomedicine.

[2]  T. Chan,et al.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.

[3]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[4]  D. Carbone,et al.  First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer , 2017 .

[5]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[6]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[7]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[8]  Donavan T. Cheng,et al.  PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. , 2017, JCO precision oncology.

[9]  M. Socinski,et al.  First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[10]  M. Bosenberg,et al.  Melanocytic nevi and melanoma: unraveling a complex relationship , 2017, Oncogene.

[11]  B. Bastian,et al.  RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. , 2017, Cancer cell.

[12]  Catherine A. Shang,et al.  Whole-genome landscapes of major melanoma subtypes , 2017, Nature.

[13]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[14]  D. Schadendorf,et al.  Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. , 2017, The Lancet. Oncology.

[15]  L. Saal,et al.  NF1‐mutated melanoma tumors harbor distinct clinical and biological characteristics , 2017, Molecular oncology.

[16]  D. Schadendorf,et al.  Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. , 2016, The Lancet. Oncology.

[17]  J. Luke,et al.  Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma , 2016, Proceedings of the National Academy of Sciences.

[18]  P. A. Futreal,et al.  Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set , 2016, BMC Medicine.

[19]  K. Flaherty,et al.  Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Matthew Wongchenko,et al.  Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. , 2016, The Lancet. Oncology.

[21]  J. Sosman,et al.  Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum , 2016, Pigment cell & melanoma research.

[22]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[23]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[24]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[25]  J. McQuade,et al.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.

[26]  C. Berking,et al.  Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. , 2015, European journal of cancer.

[27]  R. Dummer,et al.  The Genetic Evolution of Melanoma from Precursor Lesions. , 2015, The New England journal of medicine.

[28]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[29]  R. Schreiber,et al.  The odds of immunotherapy success , 2015, Science.

[30]  M. Valsecchi Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[31]  A. Aplin,et al.  RAC1 P29S regulates PD‐L1 expression in melanoma , 2015, Pigment cell & melanoma research.

[32]  I. Yeh,et al.  Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion , 2015, Pigment cell & melanoma research.

[33]  S. Ariyan,et al.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas , 2015, Nature Genetics.

[34]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[36]  M. Stratton,et al.  High burden and pervasive positive selection of somatic mutations in normal human skin , 2015, Science.

[37]  D. Schadendorf,et al.  BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. , 2015 .

[38]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[39]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[40]  A. Iafrate,et al.  Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies , 2015, Cancer Immunology Research.

[41]  J. Larkin,et al.  Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. , 2015, Cancer cell.

[42]  N. Bardeesy,et al.  mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. , 2015, Cancer cell.

[43]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[44]  Richard F. Kefford,et al.  Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients , 2014, Clinical Cancer Research.

[45]  K. Dutton-Regester,et al.  BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib , 2014, Pigment cell & melanoma research.

[46]  Gordon B Mills,et al.  The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. , 2014, Cancer research.

[47]  D. Schadendorf,et al.  TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. , 2014, Journal of the National Cancer Institute.

[48]  S. Puig,et al.  Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions , 2014, International journal of cancer.

[49]  S. Fox,et al.  Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines , 2014, Pigment cell & melanoma research.

[50]  G. Linette,et al.  Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. , 2014, JAMA.

[51]  B. Taylor,et al.  Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. , 2014, Cancer research.

[52]  Michael A. Davies,et al.  Pathways and therapeutic targets in melanoma , 2014, Oncotarget.

[53]  Iwei Yeh,et al.  Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy , 2013, Pigment cell & melanoma research.

[54]  A. D. Van den Abbeele,et al.  Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[56]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[57]  A. Iafrate,et al.  NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM). , 2013 .

[58]  S. O'toole,et al.  BRAF inhibitor activity in V600R metastatic melanoma. , 2013, European journal of cancer.

[59]  K. Flaherty,et al.  Elucidating distinct roles for NF1 in melanomagenesis. , 2013, Cancer discovery.

[60]  M. Berger,et al.  Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma , 2013, Clinical Cancer Research.

[61]  S. Kweon,et al.  BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas. , 2013, The Journal of investigative dermatology.

[62]  Junfeng Xia,et al.  BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. , 2012, Cancer discovery.

[63]  A. Rademaker,et al.  The role of 8q24 copy number gains and c-MYC expression in amelanotic cutaneous melanoma , 2012, Modern Pathology.

[64]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[65]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[66]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[67]  Matthew J. Davis,et al.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.

[68]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[69]  Lauren E Haydu,et al.  Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma , 2012, Clinical Cancer Research.

[70]  William Pao,et al.  Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials , 2012, PloS one.

[71]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[72]  K. Flaherty,et al.  Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  G. Mann,et al.  Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  J. Malvehy,et al.  Genome-wide association study identifies three loci associated with melanoma risk , 2009, Nature Genetics.

[75]  R. DePinho,et al.  BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.

[76]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  S. Puig,et al.  Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents , 2006, Journal of Medical Genetics.

[78]  Stephen B Gruber,et al.  BRAF and NRAS mutations in melanoma and melanocytic nevi , 2006, Melanoma research.

[79]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[80]  Takayuki Kosaka,et al.  Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  D. Tuveson,et al.  Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. , 2005, Cancer research.

[82]  Rossella Bertulli,et al.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.

[83]  F. Haluska,et al.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. , 2004, The Journal of investigative dermatology.

[84]  Ajay N. Jain,et al.  Determinants of BRAF mutations in primary melanomas. , 2003, Journal of the National Cancer Institute.

[85]  Rui Qiao,et al.  BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. , 2003, Cancer research.

[86]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[87]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  P S Harper,et al.  Molecular genetics of neurofibromatosis type 1 (NF1). , 1996, Journal of medical genetics.

[89]  W. Clark,et al.  Germline p16 mutations in familial melanoma , 1994, Nature Genetics.

[90]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[91]  D. Mccormick Sequence the Human Genome , 1986, Bio/Technology.

[92]  Alexander V Penson,et al.  Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. , 2018, Cancer cell.

[93]  Antoni Ribas,et al.  Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. , 2014, Cancer discovery.

[94]  Jeffrey W. Clark,et al.  Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer , 2014 .

[95]  T. Eberlein,et al.  Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .

[96]  Jochen K. Lennerz,et al.  An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair / fair skin background , 2012 .

[97]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[98]  International Human Genome Sequencing Consortium Initial sequencing and analysis of the human genome , 2001, Nature.